SIGA,
SIGA To Present at the 26th Annual JPMorgan Healthcare Conference
Monday January 7, 2:50 pm ET
Dr. Eric Rose to be a Featured Panel Member of JPMorgan's Biodefense & Pandemic Flu Presentation
NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens and protect the population at large, today announced that its Chief Executive Officer, Dr. Eric Rose, will present an overview of the company’s business activities at the upcoming 26th Annual JPMorgan Healthcare Conference to be held in San Francisco on January 10, 2007 at 12:30 p.m. Pacific time.
ADVERTISEMENT
Dr. Rose has also been invited to participate as a panel member of the JPMorgan Biodefense & Pandemic Flu Presentation, moderated by Ipsita Smolinski, JPMorgan’s healthcare policy research analyst. Keynote speakers at this special session include Dr Rajeev Venkayya, former Special Assistant to the President and Senior Director for Biodefense at the White House National Security Council and Brian Kamoie, Deputy Assistant Secretary at the US Department of Health and Human Services. Both keynotes will speak to the US government’s understanding of the various biological, chemical, radiological and nuclear threats and how they have evolved over time, including the latest on special government programs and awards to counter biothreats and pandemic flu.
About SIGA Technologies, Inc.
SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential biowarfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA’s Web site at www.siga.com.
Contact:
Investor Relations:
Cameron Associates
Al Palombo, 212-554-5488
al@cameronassoc.com
--------------------------------------------------------------------------------
Source: SIGA Technologies, Inc. |
